

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

2801630002

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/230463

INTERNATIONAL APPLICATION NO.

PCT/GB97/01991

INTERNATIONAL FILING DATE

24th July 1997

PRIORITY DATE CLAIMED

24th July 1996 and 15th November 1996

TITLE OF INVENTION

GALANIN

APPLICANT(S) FOR DO/EO/US

Wynick, David

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 18 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
A **SECOND** or **SUBSEQUENT** preliminary amendment.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☒ Certificate of Mailing by Express Mail
19. ☒ Other items or information:

Drawings, Figure 1 - Figure 9; Authorization for EOT; Return Receipt Postcard

Copies of the Annexes are included with the International Preliminary Examination Report (PCT/IPEA/409)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

INTERNATIONAL APPLICATION NO.

ATTORNEY'S DOCKET NUMBER

PCT/GB97/01991

23016.0002

20. The following fees are submitted:.

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☒ Search Report has been prepared by the EPO or JPO \$840.00 ~~\$930.00~~
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) ~~\$720.00~~
- ☐ No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) ~~\$790.00~~
- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO ~~\$1,070.00~~
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) ~~\$98.00~~

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$840.00

Surcharge of **\$130.00** for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). ☐ 20 ☐ 30

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	23 - 20 =	3	x \$18.00
Independent claims	10 - 3 =	7	x \$78.00

\$54.00

\$546.00

Multiple Dependent Claims (check if applicable). ☒

\$260.00

TOTAL OF ABOVE CALCULATIONS =

\$1,700.00

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). ☐

\$0.00

SUBTOTAL =

\$1,700.00

Processing fee of **\$130.00** for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). ☐ 20 ☐ 30 +

\$0.00

TOTAL NATIONAL FEE =

\$1,700.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐

\$0.00

TOTAL FEES ENCLOSED =

\$1,700.00

Amount to be:	\$
refunded	
charged	\$

☒ A check in the amount of **\$1,700.00** to cover the above fees is enclosed.☐ Please charge my Deposit Account No. in the amount of to cover the above fees.
A duplicate copy of this sheet is enclosed.☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **14-0629** A duplicate copy of this sheet is enclosed.**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

David G. Perryman, Esquire
NEEDLE & ROSENBERG, P.C.
127 Peachtree Street, N.E., Suite 1200
Atlanta, GA 30303, US
404-688-0770

SIGNATURE

Janice A. Kimpel

NAME

42,734

REGISTRATION NUMBER

DATE

300 Rec'd PCT/PTG 22 JAN 1999

ATTORNEY DOCKET NO. 23016.0002

EXPRESS MAIL NO. EL211202857US

PATENT APPLICATION

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Wynick, David

Serial Number: Unassigned

Filed: January 22, 1999

For: "GALANIN"

Group Art Unit: Unassigned

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

January 22, 1999

Sir:

Prior to the examination of this application, Applicant respectfully requests entry of the following amendments:

IN THE CLAIMS

Please amend claim 8 to read as follows:

8.(Amended) The [A] mammal of [according to] claim 7, wherein [in which] the galanin gene has been inactivated.

Please amend claim 9 to read as follows:

9.(Amended) The [A] mammal of [according to] claim [7 or] 8, wherein [in which] the galanin gene has been inactivated by at least partial deletion.

Please amend claim 10 to read as follows:

10. (Amended) The [A] mammal of [according to] claim 9, wherein the partial deletion [in which the portion] of the galanin gene occurs between the *Bam*HI and *Bgl*II restriction sites designated 'Exons 1-5' in [Fig.] Figure 3, [has been deleted].

Please amend claim 11 to read as follows:

11. (Amended) The [A] mammal of [according to any of] claim[s 7 to 10 which] 7, 8, 9, or 10 wherein the mammal is a rodent.

Please amend claim 12 to read as follows:

12. (Amended) The [A] rodent [according to] of claim 11 [which] wherein the rodent is a mouse.

ATTORNEY DOCKET NO. 23016.0002
EXPRESS MAIL NO. EL211202857US
PATENT APPLICATION

Please amend claim 13 to read as follows:

13. (Amended) Tissue, cells and cell lines derived from the [a] mammal [, rodent or mouse according to any of claims 7 to 12] of claim 7, 8, 9, 10, or 11 or the rodent of claim 12.

Please amend claim 15 to read as follows:

15. (Amended) [The] Use of the [a] mammal [, rodent or mouse according to any one] of claim[s 7 to 12 or the tissue cells and cell lines according to claim 13 or 14] 7, 8, 9, 10, or 11 or the rodent of claim 12 in an assay to determine a biological effect of galanin.

Please add the following new claim:


--17. Use of the tissue, cells and cell lines of claim 13 in an assay to determine a biological effect of galanin.--

Claims 1-16 are currently pending in the application. Claims 8, 9, 10 and 12 have been amended to place them in proper format. Claims 11, 13, and 15 have been amended to place them in proper multiple dependent claim format. Support for new claim 17 is found in claim 15 as originally filed and throughout the specification. No new matter is added by these amendments. Applicants await action on the merits.

ATTORNEY DOCKET NO. 23016.0002
EXPRESS MAIL NO. EL211202857US
PATENT APPLICATION

It is believed that no fee is due. However, the Commissioner is hereby authorized to charge any deficiency to Deposit Account No. 14-0629.

Respectfully submitted,
NEEDLE & ROSENBERG, P.C.


Janice A. Kimpel
Registration No. 42,734


NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811
(404) 688-0770

Express Mail No. EL211202857US

Certificate Of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail No EL211202857US in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on this the 22nd day of January, 1999.


Janice A. Kimpel


Date

300 Rec'd PCT/PT9 22 JAN 1999

GALANIN

This invention relates to galanin, including analogues thereof and its uses.

Galanin is a 29 amino acid neuropeptide which was first isolated from porcine intestine in 1983. Subsequently, the cDNA for galanin was cloned from a rat anterior pituitary library in 1987. Nucleotide and amino-acid sequence analysis suggests that galanin is unrelated to any of the other known families of regulatory peptides, and remains the only member of its family. The N-terminal portion of galanin is highly conserved between species, there being variation in the C-terminal portion.

Galanin has a widespread distribution in the peripheral and central nervous systems, gut and pancreas. It is found in highest levels in the median eminence of hypothalamus and in the pituitary

WO92/12997 (General Hospital Corporation), published in 1992, discloses the sequence of human galanin. There is a discussion of studies by other workers involving the administration of rat galanin or its N-terminal fragments to augment the effect of morphine and this patent application suggests that galanin can be expected to exhibit analgesic effects such that it may be administered alone or in combination with other analgesics. The application claims the use of galanin or its analogues in the treatment of pain and the use of galanin antagonists in the treatment of certain other conditions.

WO92/20709 (Astra AB) discloses a number of putative galanin antagonists. The antagonists which are described are all based on the first 12 amino acids of galanin followed by partial sequences of other peptides i.e. chimeric peptides. Some may be agonists, some antagonists and some may be both depending on the receptor subtype. The application discloses that the antagonists may be useful for treatment of insulin-, growth hormone-, acetyl choline-, dopamine-, Substance P-, Somatostatin-, and noradrenaline-related conditions including endocrinology, food intake, neurology and psychiatry, Alzheimer's type dementia, analgesia, intestinal disease. The application discloses the results of studies using some of the antagonists described therein on various

Article 34 Amended sheet

2

effects such as galanin inhibition of glucose stimulated insulin release; galanin induced inhibition of scopolamine induced ACh hippocampal release; galanin induced facilitation of the flexor reflex; the displacement of bound iodinated galanin in membrane binding studies. There is a suggestion in the application that the antagonists may be indicated for analgesia but there is no disclosure in the application of results to this effect.

Approximately 2-4% of the Western population suffer from diabetes mellitus and, of those people, 10-15% suffer from chronic pain and numbness in their extremities-termed "painful neuropathy". Present techniques for management of painful neuropathy are inadequate.

Alzheimer's disease is a major cause of morbidity worldwide the disease being characterised by loss of memory and personality changes. At an anatomical level there is a major decrease in the number of cholinergic nerves in the basal forebrain and hippocampus, which are the main area of the brain thought to process and store memories. Previous work has shown that galanin is also expressed in these hippocampal nerves and the levels of galanin are two fold elevated in the brains of patients with Alzheimer's disease.

The present invention relates to the generation of a mouse with targeted disruption of the galanin gene; experiments using the mouse, and the implication of the results of those experiments for the treatment of disease. In particular, the invention relates to the generation of a mutant mouse carrying a loss-of-function germ-line mutation of the galanin locus. The inactivating mutation has been introduced into the mouse genome utilising targeted mutagenesis in embryonic stem cells by homologous recombination. The mutation, when bred to homozygosity on the inbred 129sv background, affects feeding behaviour, lactation and pain sensitivity. The mutation may also affect memory and behaviour, sexual reproduction and fertility and insulin secretion with resultant changes in circulating blood glucose levels.

According to first aspect of the invention there is provided the use of a galanin agonist in the preparation of a medicament for the treatment of nerve damage.

Article 34 Amendment

3

According to a second aspect of the invention there is provided a method of healing, preferably repairing, nerve damage in a subject comprising administering to the subject a galanin agonist.

According to another aspect of the invention there is provided a method of treatment of Alzheimer's disease, the method comprising administering a galanin agonist to a subject.

In a further aspect of the invention, there is provided a method of improving memory, enhancing memory and improving cognitive function, comprising administering a galanin agonist to a subject. Advantageously, such treatment may be used in the treatment of restoring memory after injury, trauma or in Alzheimer's disease.

The invention further provides galanin agonists suitable for use in the treatment of Alzheimer's disease and in the improvement of memory and cognitive function. Also, the invention provides the use of a galanin agonist in the preparation of a medicament for the treatment of Alzheimer's disease and related diseases and conditions, and in enhancing memory and cognitive function.

According to a further aspect of the invention there is provided a mammal, preferably a rodent, which lacks a functional galanin gene. The term "galanin" embraces all known galanins including, for example, human, rat, murine and porcine galanin and also analogues of galanin having the biological activity of galanin. The galanin gene may have been inactivated by at least partial deletion of the galanin gene sequence between the Bam HI and BglII restriction sites, designated 'Exons 1-5' in the accompanying Fig. 3. Where the mammal is a rodent, it is preferably a mouse. Other mammals such as sheep and rats are contemplated.

According to another aspect of the invention there is provided tissue, cells and cell lines derived from the mammal in accordance with the first aspect of the invention. Preferably, the tissue, cells or cell lines include cells from pancreas, pituitary, cortex, dorsal root ganglia, or are derived from such cells.

AMENDED SHEET

Article 34 Amendment

4

The mammal or tissue, cells and cell lines of the invention may be used in an assay to study one or more biological effects of galanin. The biological effect may be selected from, for example, prolactin secretion, appetite, memory, behaviour, pain, autotomy following axotomy, growth or the repair of nerve damage.

Embodiments of the invention will now be described, by way of example only, with reference to the accompanying drawings Figures 1 to 16 in which:

Fig. 1 illustrates the genomic structure of mouse galanin;

Fig. 2 illustrates the targeting vector used in producing the rodent of the invention;

Fig. 3 illustrates the specific recombination event in the production of the rodent in accordance with the invention;

Fig. 4 illustrates the genotype of the progeny determined using Southern blotting and by PCR demonstrating identical results from the same litter derived from a mating of two heterozygote animals;

Fig. 5 illustrates the effect of galanin inactivation on short term regeneration of sensory neurons;

Fig. 6 illustrates the effect of galanin inactivation on long term regeneration of sensory neurons;

Fig 7 illustrates expression of an exon 6-specific riboprobe to study the distribution of galaninergic neurons in the brain and dorsal root ganglion of wildtype and mutant mice;

Fig 8 illustrates the effects of galanin inactivation on the generation of long term potentiation in the stratum radiatum area of the hippocampus; and

AMENDED SHEET

Article 34 Amendment

5

Fig 9 illustrates the effects of galanin inactivation on the generation of long term potentiation in the stratum oriens area of the hippocampus.

To generate a mouse knockout, that is the introduction into the mouse genome of either a loss- or gain-of-function mutation of a specific gene locus (according to the procedure described in Kuehn, M. R. *et al* Nature. 1987; 326: 295-8; Thomas, K. R. and Capecchi, M. R. Nature. 1986; 324: 34-8) , entails a number of steps:- (1) the cloning of the mouse genomic locus of interest; (2) the construction of a targeting vector such that the locus/gene of interest is modified to inactivate or alter its structure and function in some way; (3) introduction of the targeting vector into an embryonic stem cell library and selection and identification of single cell clones in whom the appropriate correct targeting event has taken place and in whom the normal chromosomal number is unchanged; and (4) introduction of such clones into 3.5 day old blastocysts and the resulting chimeric mice mated to wild types of the opposite sex. The resulting offspring demonstrated to carry the mutation are thus heterozygotes and, by appropriate mating, homozygotes for the introduced mutation are bred.

As a first step the murine *galanin* gene was cloned. A mouse genomic library (Ehrlich, E. *et al* Gene. 1987; 57: 229-37) was screened using the full length rat *galanin* cDNA as a probe under high stringency. Two cosmid clones were identified spanning 60Kb around the galanin locus. Using 5' and 3' probes from the rat cDNA a 14 Kb region of DNA containing the entire gene was subcloned and partially sequenced. From the genomic sequence, primers were designed complementary to untranslated exonic regions of the gene. A 630bp fragment was generated by RT-PCR (Kit supplied by INVITROGEN BV, The Netherlands) using adult female whole brain as a source of mRNA. Subsequent sequencing of this fragment demonstrated that mouse and rat galanin are 100% identical at the protein level and 94.8% at the nucleotide level. The genomic structure of the mouse gene (Fig. 1) is identical to that of the rat gene. The gene spans 4.8Kb and consists of six exons. The translation start site (AUG) starts at the first base of exon two, the coding region for galanin extends across exons three and four with the stop codon (UGA) in the middle of exon six.

AMENDED SHEET

Article 34 Amended sheet

6

Using the 14Kb subclone described above, a positive/negative selection targeting vector was constructed (Fig. 2). The mutation introduced removes the first five exons containing the entire coding region of the galanin peptide (Fig. 3).

In Fig. 3: A and B are the sites of the external probes used to screen the ES cells for the appropriate integration of the construct.

Neo = neomycin resistance gene

HSV-TK= herpes simplex virus thymidine kinase gene

B = *Bam*HI

E = *Eco*RI

X = *Xho*I

Bg = *Bgl*II

In particular, the targeting vector removes a 3.2Kb stretch of DNA and thus removes the first 5 exons of the galanin gene. The exact sites flanking the stretch of DNA removed are 5' - the *Bam* HI site 10bp downstream from the transcriptional start site and the 3' site is the *Bgl*II site in the middle of intron 5. These sites are indicated with asterisks in Fig. 3. Other sites that could be used are the same 5' site and a differing 3' *Xho*I site in intron 4 which would remove only 2.9Kb of DNA and thus remove only first 4 exons.

This vector was linearised and electroporated into the E14 embryonic stem-cell (ES) line (Hooper, M. *et al* Nature. 1987; 326: 292-5). Restriction mapping of the wildtype locus with *Bgl*II generates a 9.3Kb fragment when probed with a 5' external probe (marked A, Fig 3), whilst the correctly targeted locus generates a 4.4 Kb fragment. In total, 9 clones were identified in which one allele of the galanin gene was correctly targeted by homologous recombination among 209 double resistant colonies yielding a targeting frequency of 4.3%. These nine clones were karyotyped, confirming euploidy, and injected

APPENDED SHEET

Article 34 Amendment

7

into 3.5 day old blastocysts from C57BL/6 mice. Germ line transmission of the disrupted galanin locus was obtained from three separate ES cell clones. Genotype of the progeny was determined using Southern blotting and by PCR (Fig 4 demonstrates identical results obtained by Southern blotting and PCR screening on the same litter derived from a mating of two heterozygotes). The mutation has been bred to homozygosity on the in-bred 129sv strain and all data presented is from mice on this background.

1. Results of genotype analysis of live births are in the expected ratio predicted by Mendelian genetics and the sex ratio is 1:1. Galanin levels were measured by radioimmunoassay and immunocytochemistry in areas previously demonstrated to express galanin at high levels and include brain, pituitary, spinal cord, dorsal root ganglion, stomach, small intestine and uterus. Galanin levels in heterozygotes for the deletion were 50% of wild type controls whilst Galanin levels in the homozygotes for the deletion were undetectable in all cases.

A comparison of levels of galanin expression between wild type, heterozygote and mutant mice in several body tissues is shown in Table 1.

Table 1

Genotype	Cortex	Hypothalamus	Anterior Pituitary	Stomach	Duodenum	Ileum
+/+	5.78±0.3 3	110.34±7.81	0.42±0.07	27.46±1.91	122.90±11.6 0	267.43 ±13.46
+/-	2.91±0.2 1	53.82±3.76	0.21±0.04	13.8±0.83	68.36±5.67	125.87 ±7.55
-/-	UD	UD	UD	UD	UD	UD

All values are mean galanin-LI pmol/g ± SEM, other than the female anterior pituitary which is expressed as pmol/gland ± SEM. UD=Undetectable

It will be seen that galanin was not detected in any of the tissues tested in the homozygous mutant mouse, and decreased by 50% in the heterozygous mutant mouse.

2. The regenerative abilities of sensory axons in the sciatic nerve were directly measured by the pinch test (Danielsen, N., Kerns, J.M., Holmquist, B., Zhao, Q., Lundborg, G. & Kanje, M. Brain Res. 681, 105-108 1995). Following nerve crush, sensory axons regenerate into the distal nerve and can be stimulated by a subsequent nerve pinch, which elicits a reflex abdominal motor response. The foremost regenerating axons are located by pinching consecutive segments of the nerve in a distal to proximal direction until a reflex is observed and the distance from the nerve crush can be calculated. Regeneration showed a statistically significant reduction of 30-40% in homozygotes compared to wild type mice at 2, 4 and 6 days after nerve crush (Fig. 5). Regeneration was intermediate in heterozygous mice but was still significantly different from wild type animals.

To test whether the reduced rate of regeneration in galanin-deficient mice affects functional recovery after a crush injury, we tested a behavioural correlate of regeneration using the toe spreading index (Hoogeveen, J.F., Van Der Kracht, A.H., Wondergem, J., Gonzalez Gonzalez, D. & Haveman, J. Neurotoxicology. 14, 1-7 1993). Rodents spread the toes on their hind feet upon contact with a solid surface, a response which requires sensory innervation. Toe spreading is, therefore, lost after axotomy until sensory axon re-innervation occurs. The toe spreading distance was measured for 6 weeks after unilateral right sciatic nerve crush and compared to the intact contralateral (left) foot. Whilst toe spreading in wild-type mice returned to normal within 3 weeks of sciatic nerve crush, functional regeneration was still incomplete at six weeks in the mutant mice (Fig 6).

3. The decreased regeneration and autotomy in the galanin-deficient mice might be related to the death of neurons following axotomy, especially those neurons which would normally express galanin after injury. To test whether galanin is essential for the survival of neurons during development, we studied the distribution of galaninerbic neurons in wild type and mutant mice. Since we were unable to visualise the galaninerbic neurons in the mutant animals at the protein level we studied expression of the mRNA using a riboprobe

Article 34 Amendment

9

specific for exon six (marked B, see Figure 3). In order to confirm the survival of other populations of galanin expressing neurons, the exon 6-specific riboprobe was used to visualise galaninergic neurons in the hippocampus and the paraventricular nucleus of the hypothalamus of adult wild-type and mutant mice (Fig 7). No differences in expression were observed between the groups suggesting that neuronal development are normal in these animals and not galanin dependent.

We went on to use the exon 6-specific riboprobe to study the distribution of galaninergic neurons in the DRG two weeks after sciatic nerve axotomy. A marked up-regulation in the levels and number of cells expressing galanin was observed in the DRG neurons of wild type mice (Fig 7). However, there was no expression in the homozygous galanin-deficient mice, suggesting that galanin is required for these cells to survive axotomy.

These results relating to regeneration and cell survival are particularly significant in that the results indicate that galanin gene is the first gene to affect regeneration of the peripheral nervous system.

Accordingly, the invention contemplates the use of a galanin agonist in the treatment of peripheral sensory neuropathy resulting, for example, from diabetes mellitus or trauma (such as that caused by traffic accidents).

4. Galanin has been implicated in the aetiology of Alzheimer's disease. Hippocampal galanin expression is increased in cholinergic neurones as acetylcholine and choline acetyl transferase (ChAT) levels fall. Administration of galanin decreases learning behaviour in a number of mouse models, the converse is also true when galanin antagonists are infused. We measured long term potentiation (LTP) in wild type and mutant mice. LTP is an electrophysiological test where specific nerves in the hippocampus are stimulated by an electric shock: Davies CH, Collingridge GL. *J. Physiol. Lond.* 1996;496: 451-470; Davies CH, Starkey SJ, Pozza MF, Collingridge GL. *GABA Nature* 1991;349:609-611. This procedure is done *in-vitro* using brain slices from recently killed animals. Results show that LTP is decreased by 50% in the stratum oriens at the 80 minute time point in the mutants compared to wild-type mice (Fig 9 A vs C). In contrast no difference was found in LTP

Article 34 Amendment

10

measured in the stratum radiatum. Galanin is found at high levels in the stratum oriens but NOT in the stratum radiatum. Our data, thus far, demonstrates a decrease in LTP in the mutants implying a decrease in memory and cognition - tests to assess these function are being conducted. These data show that a galanin agonist is useful in the treatment of Alzheimer's disease and associated memory loss with an enhancement in memory and cognition.

Article 34 Amendment

11

Claims

1. The use of a galanin agonist in the preparation of a medicament for the treatment of nerve damage.
2. A method of treating nerve damage in a mammal comprising administering a galanin agonist to that mammal.
3. A method of treating Alzheimer's disease comprising administering a galanin agonist to a subject.
4. The use of a galanin agonist in the preparation of a medicament for the treatment of Alzheimer's disease.
5. A method of improving memory, enhancing memory functions and improving cognitive function, the method comprising administering a galanin agonist to a subject.
6. The use of a galanin agonist in the preparation of a medicament for improving memory and other cognitive functions.
7. A transgenic or other genetically modified mammal which lacks a functional galanin gene.
8. A mammal according to claim 7 in which the galanin gene has been inactivated.
9. A mammal according to claim 7 or 8 in which the galanin gene has been inactivated by at least partial deletion.
10. A mammal according to claim 9 in which the portion of the galanin gene between the *Bam*HI and *Bgl*II restriction sites designated 'Exons 1-5' in Fig. 3 has been deleted.
11. A mammal according to any of claims 7 to 10 which is a rodent.
12. A rodent according to claim 11 which is a mouse.

AMENDED SHEET

Article 34 Amendment

12

13. Tissue, cells and cell lines derived from a mammal, rodent or mouse according to any of claims 7 to 12.
14. Tissue, cells or cell lines according to claim 13 which are cells from pancreas, pituitary, cortex, dorsal root ganglia or are derived from such cells.
15. The use of a mammal, rodent or mouse according to any one of claims 7 to 12 or tissue cells and cell lines according to claim 13 or 14 in an assay to determine a biological effect of galanin.
16. The use according to claim 15 in which the biological effect is selected from diabetes and insulin secretion, appetite, growth hormone effects, lactation, prolactin over secretion, pain sensitivity, memory, behaviour, sexual reproduction and fertility.

Article 34 Amendment
1/9

GENOMIC STRUCTURE mGAL




FIG 1.

AMENDED SHEET

Article 34 Amendment

2/9

TARGETING VECTOR




Fig 2

Article 34 Amendment
3/9





Fig 3

AMENDED SHEET

Article 34 Amendment
4/9

Fig 4

BglII



PCR



Regenerative rates after a crush injury to the right sciatic nerve

Article 34 Amendment
5/9





Fig 5

AMENDED SHEET

Article 34 Amendment


6/9

Fig 6 Toe spreading index after a crush injury
to the right sciatic nerve



AMENDED SHEET


Article 34 Amendment
7/9



Article 34 Auered meet
8/9

Fig 8

LONG-TERM POTENTIATION IN STRATUM RADIATUM





ENDED SHEET

Fig 9

LONG-TERM POTENTIATION IN STRATUM ORIENS

100 Hz, 1 s TETANUS



UNDOED SHEET

Article 34 Amendment
9/9

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

☒ (X) Original ☐ Supplemental ☐ Substitute ☐ PCT

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "**GALANIN**", which is described and claimed in the specification

(check one) ☐ which is attached hereto, or
☒ which was filed on January 22, 1999, as United States Application No. (unassigned) and with amendments through January 22, 1999 (if applicable), or
☐ in International Application No. PCT/, filed, and as amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information known by me to be material to the patentability of the claims of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATIONS: (ENTER BELOW IF APPLICABLE)			PRIORITY CLAIMED (MARK APPROPRIATE BOX BELOW)	
APP. NUMBER	COUNTRY	DAY/MONTH/YEAR FILED	YES	NO
961551.0	GB	July 24, 1996	X	
9623869.6	GB	November 15, 1996	X	
PCT/GB97/01991	International	July 24, 1997	X	

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information known by me to be material to the patentability of the claims of this application as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS (MARK APPROPRIATE COLUMN BELOW)		
		PATENTED	PENDING	ABANDONED

I hereby appoint the following attorneys and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

William H. Needle	Reg. No. <u>26,209</u>	Bradley K. Groff	Reg. No. <u>39,695</u>
Sumner C. Rosenberg	Reg. No. <u>28,753</u>	Matthew D. Josephic	Reg. No. <u>P-43,699</u>
David G. Perryman	Reg. No. <u>33,428</u>	Janice A. Kimpel	Reg. No. <u>42,734</u>
Mitchell A. Katz	Reg. No. <u>33,919</u>	Tina W. McKeon	Reg. No. <u>P-43,791</u>
Gregory J. Kirsch	Reg. No. <u>35,572</u>	Mary L. Miller	Reg. No. <u>39,303</u>
Gwendolyn D. Spratt	Reg. No. <u>36,016</u>	Mark A. Murphy	Reg. No. <u>42,915</u>
Nagendra Setty	Reg. No. <u>38,300</u>	Clark G. Sullivan	Reg. No. <u>36,942</u>
Allan A. Altera	Reg. No. <u>40,274</u>	Elket V. Swope	Reg. No. <u>40,195</u>
Bryan W. Bockhop	Reg. No. <u>39,613</u>	Lawrence A. Villanueva	Reg. No. <u>P-43,968</u>
Kean J. DeCarlo	Reg. No. <u>39,954</u>	Mark A. Westhafer	Reg. No. <u>42,220</u>
LaVonda R. DeWitt	Reg. No. <u>40,396</u>		
D. Andrew Floam	Reg. No. <u>34,597</u>		


Address all telephone calls to David G. Perryman at telephone no. (404) 688-0770.

Address all correspondence to:

David G. Perryman
NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: David Wynick

Inventor's signature: 

Date: 24/2/99

Residence: Department of Medicine, Bristol University

Post Office Address: Marlborough Street, Bristol BS2 8BA, UK GBX

Citizenship: British